Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2015-04-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised through a non-public stock issuance, the timing of fund receipt, usage of the funds, balances, and compliance with regulatory requirements. The document includes detailed tables showing the use of the raised funds and confirms no changes in the use of funds during the reporting period. This is a report specifically about the use of capital raised (募集资金), which aligns with a Capital/Financing Update. It is not an annual or interim financial report, nor an announcement of a report publication. The document length is over 5,000 characters and contains substantive financial data about capital raised and used. Therefore, the best fitting category is Capital/Financing Update (CAP).
2015-04-23 Chinese
第六届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 普洛药业股份有限公司 (Puloyao Pharmaceutical Co., Ltd.) regarding the approval of the 2014 Annual Report and related reports such as the Supervisory Board's work report, financial work report, profit distribution plan, use of raised funds, internal control evaluation report, and other governance matters. It includes statements confirming the accuracy and completeness of the 2014 Annual Report and internal control evaluation, but does not contain the full annual report itself. The document length is short (1117 characters) and it is primarily an announcement of the Supervisory Board's review and approval of the annual report and related documents. This fits the category of Regulatory Filings (RNS) as it is a formal regulatory announcement rather than the full Annual Report (10-K) or Audit Report (AR).
2015-04-23 Chinese
第六届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 10th meeting of the 6th Board of Directors of 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.) held on April 23, 2015. It includes approvals of the 2014 Annual Report, Board Work Report, General Manager Work Report, Financial Work Report, profit distribution plan, and other corporate governance matters. It also includes the nomination and declaration of an independent director candidate. The document is not the annual report itself but a formal announcement of board meeting decisions, including items that require shareholder approval. It contains detailed voting results and attachments related to director nominations and company charter amendments. This type of document is best classified as Board/Management Information (MANG) because it announces changes and decisions made by the board, including director nominations and internal governance matters. It is not a full annual report (10-K), audit report (AR), or proxy solicitation (PSI). The document length and content confirm it is not a brief announcement or certification but a substantive board meeting resolution announcement.
2015-04-23 Chinese
独立董事关于对《公司内部控制自我评价报告》的独立意见
Board/Management Information Classification · 95% confidence The document contains detailed independent opinions from the independent directors of 普洛药业股份有限公司 regarding various corporate governance matters such as internal control self-evaluation, related party transactions, external guarantees, election of independent directors, accounting policy changes, profit distribution, and performance commitments related to a previous asset restructuring and non-public share issuance. The document references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial performance data and audit opinions related to the 2014 fiscal year. The content is focused on management and board oversight, internal controls, and compliance with governance and regulatory standards, rather than being a full annual report or audit report. It is not a transcript, earnings release, or capital update. The document is a formal set of independent opinions and statements from the board and independent directors, which fits best under the category of Board/Management Information (MANG).
2015-04-23 Chinese
关于授权董事长进行理财投资的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company Pu Luo Pharmaceutical Co., Ltd. regarding the authorization of the chairman to conduct financial investment using the company's idle funds. It details the investment amount, duration, risk analysis, and control measures. The document is an announcement about a capital management decision rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital usage for investment purposes.
2015-04-23 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company 普洛药业股份有限公司. It details the date of change, reasons, the new accounting policies adopted, and the impact on financial statement items. It also includes opinions from the board of directors, independent directors, and the supervisory board on the reasonableness of the change. The document does not contain full financial statements or comprehensive financial performance data but focuses on the policy change and its effects. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory announcement about accounting policy changes and corrections following a regulatory inspection, without being a full audit report or annual report itself.
2015-04-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.